@NVIDIA
  @NVIDIA
NVIDIA | Accelerate AI-Powered Drug Discovery With NVIDIA BioNeMo @NVIDIA | Uploaded 1 year ago | Updated 1 day ago
Learn More: nvda.ws/403Myhk

NVIDIA BioNeMo is a cloud service for generative AI in early drug discovery focusing on proteins and small molecules. BioNeMo can be accessed through a web interface or API endpoints and outputs can be visualized and downloaded. AI models in BioNeMo can be further fine-tuned and trained on customers’ proprietary data on DGX Cloud.

Nine AI biomolecular models are now accessible in one place:

- 3D protein structure prediction: DeepMind’s AlphaFold2, OpenFold, Meta’s ESMFold
-Protein property prediction: Meta’s ESM-2 and ESM-1nv based on Meta’s ESM-1
-Small molecule generation: AstraZeneca's MegaMolBART and Weill Cornell Medicine’s MoFlow
-Protein generation: ISMB and University of Bayreuth’s ProtGPT2
-Molecular docking: MIT Jameel Clinic’s DiffDock

#GenerativeAI #DrugDiscovery #BioNeMo
Accelerate AI-Powered Drug Discovery With NVIDIA BioNeMoNVIDIA CEO Jensen Huang Berlin Summit for EVE KeynoteGenerative AI for Drug Discovery and DesignDelivering Enterprise AI Services on Multiaccess Edge Computing: Three Perspectives from NTT GroupChatUSD - Generative AI Copilot for OpenUSD DevelopmentReimagining the Future: NVIDIA Inception Startups Showcase AI InnovationsWhat’s Next in AI: NVIDIA’s Jensen Huang Talks With WIRED’s Lauren GoodeReinventing Retail with AI | I AM AITransform Your Business with Route OptimizationBuilding Digital Twins of Foxconn’s Robotic FactoriesEarly Edition with Microsoft and NVIDIA - The Future of MediaNVIDIA and Equinix: Comprehensive AI Solutions

Accelerate AI-Powered Drug Discovery With NVIDIA BioNeMo @NVIDIA

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER